Abstract
Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Current Pharmaceutical Design
Title:Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Volume: 20 Issue: 39
Author(s): Linda Landini
Affiliation:
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Abstract: Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Export Options
About this article
Cite this article as:
Landini Linda, Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140417094458
DOI https://dx.doi.org/10.2174/1381612820666140417094458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Anti-Oxidative Effect of Curcumin Against Tert-Butylhydroperoxide Induced Oxidative Stress in Human Erythrocytes
The Natural Products Journal Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Alzheimer’s and Type 2 Diabetes Treatment via Common Enzyme Targeting
CNS & Neurological Disorders - Drug Targets The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Non-peptide Antagonists and Agonists of the Bradykinin B2 Receptor
Current Medicinal Chemistry Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment
Current Vascular Pharmacology Preoperative Plasma Aldosterone Levels and Postoperative Atrial Fibrillation Occurrence Following Cardiac Surgery: A Review of Literature and Design of the ALDO-POAF Study (ALDOsterone for Prediction of Post-Operative Atrial Fibrillation)
Current Clinical Pharmacology Oxidative Stress and Vascular Disease
Current Hypertension Reviews Role of Nitrosative Stress and Activation of Poly(ADP-ribose) Polymerase-1 in Cardiovascular Failure Associated with Septic and Hemorrhagic Shock
Current Vascular Pharmacology Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial: Management of Diabetes in Unique Populations
Current Diabetes Reviews Using Metformin in Pregnancy for Different Indications: Are We Any Wiser now?
Applied Clinical Research, Clinical Trials and Regulatory Affairs Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued)